Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus.

Journal Article (Journal Article;Review)

An oncolytic virus (OV) based on poliovirus (PV), the highly attenuated polio/rhinovirus recombinant PVSRIPO, may deliver targeted inflammatory cancer cell killing; a principle that is showing promise in clinical trials for recurrent glioblastoma (GBM). The two decisive factors in PVSRIPO anti-tumor efficacy are selective cytotoxicity and its in situ immunogenic imprint. While our work is focused on what constitutes PVSRIPO cancer cytotoxicity, we are also studying how this engenders host immune responses that are vital to tumor regression. We hypothesize that PVSRIPO cytotoxicity and immunogenicity are inextricably linked in essential, complimentary roles that define the anti-neoplastic response. Herein we delineate mechanisms we unraveled to decipher the basis for PVSRIPO cytotoxicity and its immunotherapeutic potential.

Full Text

Duke Authors

Cited Authors

  • Brown, MC; Gromeier, M

Published Date

  • August 2015

Published In

Volume / Issue

  • 13 /

Start / End Page

  • 81 - 85

PubMed ID

  • 26083317

Pubmed Central ID

  • PMC4550519

Electronic International Standard Serial Number (EISSN)

  • 1879-6265

Digital Object Identifier (DOI)

  • 10.1016/j.coviro.2015.05.007


  • eng

Conference Location

  • Netherlands